Skip to content
GLP-1 Desk
Menu

Head-to-head dispatch

Call-On-Doc vs Pallas Health

Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.

Dispatch #295
Call-On-Doc

Call-On-Doc is a large multi-condition online telehealth service (2M+ patients, 800k+ five-star reviews) offering a GLP-1 weight-loss program.

Marked down on: Specific visit fee and medication pricing not posted on homepage

vs
Dispatch #8Desk pick
Pallas Health

Pallas Health names all six of the pharmacies that dispense for it and two prescribing clinicians whose NPIs verify in the federal registry — then sells every GLP-1 on a single twelve-week prepay, so the advertised “/mo average” is one $597 or $897 charge divided by three.

Marked down on: There is no month-to-month rung for either compounded molecule — the funnel renders no cadence selector — so the advertised “$199/mo average” is a single $597 charge every twelve weeks divided by three

Pallas Health takes this head-to-head with the higher Desk Score, 87/100 (B+) against 61/100 (C) for Call-On-Doc. Call-On-Doc still holds its ground where its strengths line up with yours.

Desk Score, dimension by dimension

Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.

Call-On-Doc

61/100

C

Overall

Pallas Health

87/100

B+

Price transparency

20
78

State access

86
94

Molecule range

53
90

Onboarding speed

78
88

Support responsiveness

82
88

Licensing & trust

75
90

The spec sheet

FieldCall-On-DocPallas Health
SemaglutideNot disclosed$199/mo average (compounded injectable; $597 billed every 12 weeks after $139 for the first 4 weeks; no month-to-month tier is sold)
TirzepatideNot disclosed$299/mo average (compounded injectable; $897 billed every 12 weeks after $179 for the first 4 weeks; no month-to-month tier is sold)
CoverageAll 50 statesAll 50 states + DC (async in 43; 7 states plus DC require one video visit)
Brand-nameYesYes
Oral optionInjectable onlyInjectable only
Best forPatients wanting fast, no-appointment branded GLP-1 access with pharmacy insurance use.Readers who weight named pharmacies and independently verifiable prescribers above cash-flow flexibility, and who can absorb a $597 or $897 charge every twelve weeks rather than a monthly one.
Desk Score61/100C87/100B+

The verdict

Desk pick — Pallas Health

Pallas Health takes this head-to-head with the higher Desk Score, 87/100 (B+) against 61/100 (C) for Call-On-Doc. Call-On-Doc still holds its ground where its strengths line up with yours.

Choose Call-On-Doc if…

Patients wanting fast, no-appointment branded GLP-1 access with pharmacy insurance use.

Not disclosed sema · Not disclosed tirz · All 50 states

Choose Pallas Health if…

Readers who weight named pharmacies and independently verifiable prescribers above cash-flow flexibility, and who can absorb a $597 or $897 charge every twelve weeks rather than a monthly one.

$199/mo average (compounded injectable; $597 billed every 12 weeks after $139 for the first 4 weeks; no month-to-month tier is sold) sema · $299/mo average (compounded injectable; $897 billed every 12 weeks after $179 for the first 4 weeks; no month-to-month tier is sold) tirz · All 50 states + DC (async in 43; 7 states plus DC require one video visit)

Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: Call-On-Doc · Pallas Health.

Also here

CoreAge Rx tops every dispatch at 94/100

Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: flat all-in pricing, both molecules, all 50 states — no teaser-rate traps.

More head-to-heads

Or see the full comparison hub and the complete ranking.

Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.